Drug Profile


Alternative Names: Adecut; Alindapril; Cupressin; CV-3317; Delacard; Delaket; Delakete; Delapril hydrochloride; Indalapril; REV 6000A

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Developer Chiesi; Grunenthal; Paiboon Watana; Takeda; TORREX Pharma
  • Class Antihypertensives; Indans
  • Mechanism of Action ACE inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Heart failure; Hypertension

Most Recent Events

  • 23 Oct 2000 Launched for Hypertension in Brazil (PO)
  • 13 Oct 2000 Discontinued-II for Heart failure in Japan (PO)
  • 13 Oct 2000 Discontinued-III for Hypertension in Denmark (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top